Conditions

CREDENCE trial shows that canagliflozin, an SGLT2 inhibitor, lowers the risk of cardiovascular and renal events in patients with T2DM, regardless of prior history of heart failure. 

Additional benefits are observed with dose escalation of semaglutide for patients with type 2 diabetes.

Sexual health questionnaires can be used as an early detection tool for men's CVD, coronary heart disease, stroke, and T2D.  

People with diabetes are more sensitive to increased inflammatory response, contributing to a fast spread of COVID-19 infection. 

Canagliflozin, an SGLT2 inhibitor, and its impact in reducing hospitalizations and health care costs in people with type 2 diabetes.

Metformin's primary safety concern in patients with impaired renal function is its ability to cause lactic acidosis. 

Systemic review shows sex, age, comorbid conditions, insulin use, and several out-of-range lab predictors on hospital admission, all play a role in COVID-19 severity.

Are the mortality and cardiovascular benefits of SGLT-2 inhibitors limited to patients with type 2 diabetes who have established cardiovascular disease and renal disease?

Are socioeconomic factors and obesity independently related to diabetes prevalence?

Long-term diabetes may lead to signs of cognitive decline in Latino patients as early as middle age.